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Metformin Inhibits Androgen-Induced IGF-IR Up-
Regulation in Prostate Cancer Cells by Disrupting
Membrane-Initiated Androgen Signaling
Roberta Malaguarnera,* Antonella Sacco,* Alaide Morcavallo,
Sebastiano Squatrito, Antimo Migliaccio, Andrea Morrione, Marcello Maggiolini,
and Antonino Belfiore
Endocrinology (R.M., A.S., A.Morc., A.B.), Department of Health Sciences, University Magna Graecia of
Catanzaro, 88100 Catanzaro, Italy; Endocrinology (S.S.), Department of Clinical and Molecular
Biomedicine, University of Catania, Garibaldi-Nesima Hospital, 95125 Catania, Italy; Department of
General Pathology (A.Mi.), II University of Naples, Via L. De Crecchio, 7–80138 Naples, Italy; Department
of Urology and Biology of Prostate Cancer Program (A.Morr.), Kimmel Cancer Center, Thomas Jefferson
University, Philadelphia 19107; and Department of Pharmaco-Biology (M.M.), University of Calabria,
87030 Rende, Italy
We have previously demonstrated that, in prostate cancer cells, androgens up-regulate IGF-I re-
ceptor (IGF-IR) by inducing cAMP-response element-binding protein (CREB) activation and CREB-
dependent IGF-IR gene transcription through androgen receptor (AR)-dependent membrane-ini-
tiatedeffects. This IGF-IRup-regulation is notblockedby classical antiandrogensand sensitizes cells
to IGF-I-induced biological effects. Metformin exerts complex antitumoral functions in various
models and may inhibit CREB activation in hepatocytes. We, therefore, evaluated whether met-
formin may affect androgen-dependent IGF-IR up-regulation. In the AR LNCaP prostate cancer
cells, we found that metformin inhibits androgen-induced CRE activity and IGF-IR gene transcrip-
tion. CRE activity requires the formation of a CREB-CREB binding protein-CREB regulated tran-
scription coactivator 2 (CRTC2) complex, which follows Ser133-CREB phosphorylation. Metformin
inhibited Ser133-CREB phosphorylation and induced nuclear exclusion of CREB cofactor CRTC2,
thus dissociating the CREB-CREB binding protein-CRTC2 complex and blocking its transcriptional
activity. Similarly to metformin action, CRTC2 silencing inhibited IGF-IR promoter activity. More-
over, metformin blocked membrane-initiated signals of AR to the mammalian target of
rapamycin/p70S6Kinase pathway by inhibiting AR phosphorylation and its association with c-Src.
AMPK signals were also involved to some extent. By inhibiting androgen-dependent IGF-IR up-regu-
lation, metformin reduced IGF-I-mediated proliferation of LNCaP cells. These results indicate that, in
prostate cancer cells, metformin inhibits IGF-I-mediated biological effects by disrupting membrane-
initiated AR action responsible for IGF-IR up-regulation and suggest that metformin could represent
a useful adjunct to the classical antiandrogen therapy. (Endocrinology 155: 1207–1221, 2014)
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Abbreviations: AR, androgen receptor; ARwt, wild-type AR; CBP, CREB binding protein;
CRTC2, CREB regulated transcription coactivator 2; CREB, cAMP-response element-bind-
ing protein; CRTC2, CREB regulated transcription coactivator 2; FBS, fetal bovine serum;
GFP, green fluorescent protein; HEK293, human embryonic kidney 293; IGF-IR, IGF-I
receptor; IR, insulin receptor; LKB1, serine/threonine kinase 11; mTORC1, mammalian
target of rapamycin complex 1; MTT, methyl thiazolyl tetrazolium; N CREB, dominant-
negative CREB; OCT, organic cation transporter; p, phospho; p53, tumor suppressor p53;
PKB, protein kinase B; PP2, (4-amino-3-(4-chlorophenyl)-1-(t-butyl)-1H-pyrazolo[3,4-d]py-
rimidine, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine); p70S6K,
p70S6 kinase; p90RSK, 90 kDa ribosomal S6 kinase; PTEN, phosphatase and tensin ho-
mologue deleted on chromosome ten; R1881, methyltrienolone; REDD1, regulated in
development andDNAdamage 1; shRNA, short hairpin RNA; siRNA, small interfering RNA;
TSC2, Tuberous Sclerosis Complex 2.
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Androgen stimulation is critical for growth and resis-tance to apoptosis in most early-stage prostate car-
cinomas, which, therefore, are responsive to androgen de-
privation. However, the clinical benefits of androgen
deprivation are temporary, and these carcinomas may
eventually progress to castration-resistant tumors, for
which no effective treatment is currently available. The
molecular basis of androgen independency is incompletely
understood.
In response to androgens, androgen receptors (ARs)
regulate transcription by interacting with the androgen
response elements located within the promoter regions of
target genes and forming a multiprotein complex, which
contains coactivators, corepressors, histone acetyltrans-
ferases, and histone deacetylases (1). However, increasing
evidence suggests that the biological responses to andro-
gens can be additionally mediated by membrane-initiated
signals, which trigger rapid intracellular transduction
pathways like ERK, phosphoinositide 3-kinase, protein
kinase A, and protein kinase C, that may eventually acti-
vate gene transcription (2).Membrane-initiated androgen
signals appear to be enhanced in malignant prostate cells
by variousmechanisms, including increased proportion of
membrane-associatedARs and increased expression of ki-
nases (eg, c-Src) and/or adaptors that contribute to the
formationofmultiprotein complexeswithARat themem-
brane level and trigger the activation of intracellular path-
ways (3).
Androgen activity itself may contribute to the progres-
sion to castration-resistant prostate cancer by up-regulat-
ing autocrine loops involving peptide growth factors and
their cognate receptors (4).
In this context, we have previously found that andro-
gens induce a selective up-regulation of the IGF-I receptor
(IGF-IR) in prostate cancer cells and increase, in this way,
cell proliferation and invasiveness in response to IGF-I (5).
This effect occurs through the activation of membrane-
initiated signals, which require the recruitment of mem-
brane-bound AR to c-Src and subsequent activation of a
downstream signaling pathway involving c-Src/ERK/
cAMP-response element-binding protein (CREB) that
eventually stimulates the activity of the IGF-IR promoter
(5, 6). This mechanismmay open a new approach to pros-
tate cancer therapy, because it is poorly affected by classic
antiandrogens but canbe blockedbyCREB silencing or by
inhibitors of the c-Src/ERK pathway (6). The transcrip-
tional activity of CREB-dependent target genes requires
the formation of the CREB-CREB binding protein (CBP)-
CREB regulated transcription coactivator 2 (CRTC2)
complex (7). In particular, AMPK phosphorylates
CRTC2at Ser171 causing its interactionwith 14–3-3pro-
teins and sequestration in the cytoplasm.Glucose andhor-
mones lead to the dephosphorylation of CRTC2, its dis-
sociation from 14–3-3 proteins, and as a consequence, its
translocation to the nucleus, where it binds CREB and
promotes CREB-dependent transcription. Metformin
may additionally disrupt the CREB-CBP-CRTC2 com-
plex by inducing CBP phosphorylation at Ser436 (7).
In recent years, the biguanide metformin, widely used
as antidiabetic drug, has raised much interest for its anti-
cancer potential (8, 9). Indeed, metformin has shown an-
tiproliferative effects in several cancer cells, including
prostate cancer cells (10, 11). Interestingly, prostate can-
cer cells appear to be more sensitive to metformin than
normal epithelial prostate cells. In vivo, metformin in-
creases the response of prostate cells xenografts to the
antiandrogen bicalutamide (12). Anticancer effects of
metformin are mostly attributed to its ability to activate
AMPK,which, in turn, down-regulatesmammalian target
of rapamycin complex 1 (mTORC1) signaling, an essen-
tial regulator of cell growth and proliferation (8). Met-
formin has, however, pleiotropic effects and may addi-
tionally inhibit mTORC1 through AMPK-independent
pathways (13, 14). Metformin may also target ERK sig-
naling (15), reduce Ca(2)-dependent protein kinase C/
ERK and c-Jun N-terminal kinase/activator protein-1 sig-
naling pathways (16, 17), and also inhibit Akt (protein
kinase B [PKB]) activity through serine phosphorylation
of insulin receptor substrate-1 (18).
Because metformin is able to inhibit multiple signaling
pathways, we aimed at evaluating whether, in prostate
cancer cells, metformin may also affect the membrane-
initiated effects of androgens, which lead to IGF-IR up-
regulation and increased sensitivity to IGF-I. Here, we
show that metformin inhibits androgen-induced IGF-IR
up-regulation and the resulting mitogenic and invasive ef-
fects of IGF-I throughmultiplemechanisms.These include
the inhibition of transcriptional activity of CREB-CBP-
CRTC2 complex, the inhibition of mTORC1/p70S6 ki-
nase (p70S6K) pathway, and the disruption of AR/c-Src
interaction.
Materials and Methods
Materials
The following materials were purchased from the indi-
cated manufacturers: metformin, methyltrienolone (R1881),
Src activity inhibitor (4-amino-3-(4-chlorophenyl)-1-(t-butyl)-
1H-pyrazolo[3,4-d]pyrimidine, 4-Amino-5-(4-chlorophenyl)-
7-(t-butyl)pyrazolo[3,4-d]pyrimidine) (PP2), and rapamycin
from Sigma Chemical Co; fetal calf serum and Opti-MEM from
Gibco Laboratories; temsirolimus from DBA; and Metafectene
PRO fromBiontex LaboratoriesGmbH.R1881, ormethyltrien-
olone, is a synthetic androgen that is considered the gold stan-
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dard AR agonist for in vitro studies because of its excellent sta-
bility and its inability to undergo aromatization.
The c-Src/AR interaction inhibitory peptide (S1) has been
previously described (19).
LNCaP human prostate cancer cells and human embryonic
kidney 293 (HEK293) were obtained from the American Type
Culture Collection.
The human AR construct was provided by Dr A.O. Brink-
mann. The dominant-negative CREB (NCREB) construct was
provided by Dr C. Vinson. Rat IGF-IR promoter sequences
cloned into pGL3 vector were provided by Dr C.T. Roberts Jr.
The CRE reporter was from SABiosciences. The specific silencer
Select Predesigned small interfering RNA (siRNA) for CRCT2,
AMPK (1- and 2-subunit), regulated in development and
DNA damage 1 (REDD1), the negative control siRNA, and
the lipofectamine RNAiMax were purchased from Life
Technologies.
Western blot analysis
Subconfluent cells were serum starved and stimulated with
10nM sex steroids for the indicated times and lysed in Laemmli
buffer. Cell lysates were subjected to Western blot analysis, as
previously described (20), using the following antibodies: anti-
IGF-IR, anti-AR (clone 441), anti-IR, anti--tubulin, anti-tumor
suppressor p53 (p53), and anti-c-Src (B-12) (Santa Cruz Bio-
technology, Inc); antiphospho-CREB (clone 1B6), anti-CREB
(clone 86B10), anti-phospho (p) Akt(S473), anti-Akt, anti-
pERK1/2(T202/Y204), anti-ERK1/2, anti-pp70S6K(T389), anti-
p70S6K, and anti-AMPK (Cell Signaling Technology); anti-CRTC2
and anti-CRTC2(S171) (Antibodies-Online); anti-REDD1 (Pro-
teinTech Group, Inc); and anti-phospho tyrosine clone 4G10
(EMD Millipore).
Transient transfection and reporter assays
LNCaP andHEK293 cells were transiently transfected as de-
scribed previously (6). Twenty-four hours after transfection,
cells were serum starved for additional 24 hours and incubated
with sex steroids (10nM), metformin (10mM), or vehicle. For
luciferase assay, cells were stimulated for 24 hours, lysed, and
processed as described previously (6).
Gene silencing by short hairpin RNA (shRNA) or
siRNA
For shRNA experiments, cells were transfected with a mix-
ture containing Opti-MEM, Metafectene PRO, 0.5 g of either
4different shRNAsagainstCREBor scramble shRNAs.Twenty-
four hours after transfection, cells were serum starved and
treatedwithmetformin (10mM)with orwithoutR1881 (10nM)
for 24 hours and then processed for Western blot analysis. For
siRNA experiments, cells were transfected with a mixture con-
tainingOpti-MEM,LipofectamineRNAiMax, and either 10nM
scramble siRNA or a mixture of 2 or 3 siRNA specific for the
transcript of interest. Twenty-four hours after transfection, cells
were incubated with fresh medium and transfected with either
IGF-IR-Luc orCRE-Luc (0.5g/well) and green fluorescent pro-
tein (GFP) (0.1g/well), usingmetafectene PRO.After 12 hours,
cellswere serumstarved for10hours and treatedwithmetformin
(10mM) with or without R1881 (10nM) for 24 hours and then
processed for luciferase assay..
Immunoprecipitation
Cells were serum starved for 24 hours and then incubated
with metformin (10mM) or PP2 (10M) for the indicated time
points, followed by 10nMR1881. Cell lysates were subjected to
immunoprecipitation, as previously described (20).
Immunofluorescence
Cells were serum starved and subjected to specific treatments
as indicated. Then, cells were fixed in 4% paraformaldehyde,
permeabilized with PBS/0.1% Triton X-100, blocked with PBS/
0.05% Triton X-100/0.1% BSA, and incubated with primary
antibody (CRCT2) for 1 hour. Cells were then washed with PBS
and incubated with Alexa-conjugated (Alexa Fluor 594 or 488)
secondaryantibodies (Molecular Probes) for1hour.Tovisualize
the cytoplasm, the cells were incubated with Alexa-conjugated
phalloidin (Molecular Probes) for an additional 30minutes. Cell
nuclei were counterstained with Hoechst. Epifluorescence mi-
croscopy was performed with an Olympus microscope. The im-
ages were digitally acquired with an Orca CCD camera
(Hamamatsu) and processed with Image-Pro Plus 4.0 software
(Media Cybernetics).
Cell viability assay
Cell viability was measured by the methyl thiazolyl tetrazo-
lium (MTT) test (Amersham Biosciences). Cells were serum
starved for 24 hours in medium without phenol red and pre-
treated for 4 hours with metformin (10mM) followed by R1881
exposure (10nM) for further 24 hours. The medium was then
replaced with R1881-free medium containing 1% stripped se-
rum in the presence or not of metformin (10mM). After 4 hours,
cellswere incubated in thepresenceor absenceof 10nMIGF-I for
additional 24 hours. The cells were then incubated with medium
containing 0.5-mg/mLMTT. After 4 hours, cells were dissolved in
100Lofa solutioncontainingdimethyl sulfoxideplus2.5%com-
plete medium, and formazan absorbance was read at 405 nm.
Invasion assay
The ability of cells to invade collagen was measured with
Boyden’s chamber technique (21) Cells, serum starved for 24
hours, were incubated with or without metformin (10mM) and
R1881 (10nM) for further 24 hours. Cells were then removed
from plates with 0.01% trypsin and allowed to migrate for 18
hours in response to 10nM IGF-I as previously described (22).
Soft-agar colony formation assay
Anchorage-independent growthwas assessedby the soft-agar
assay. Briefly, 6-well plates were first plated with medium con-
taining 10% fetal bovine serum (FBS) and 0.8% agar. Next,
1000 cells were suspended in medium containing 10% fetal bo-
vine serum (FBS) plus 0.3% agar, and the cell suspension was
platedon topof the first layer. Topagarwas coveredwith culture
medium alone (basal) or containing metformin (10mM) with or
without R1881 (10nM), and the plates were maintained in the
tissue-culture incubator. Cells were stimulated twice a week for
3 weeks. Colonies formed were stained with 0.5-mg/mL MTT
and photographed.
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Cell cycle evaluation
Cells synchronized for 24 hours in serum-free medium with-
out phenol red were pretreated for 4 hours with metformin
(10mM) followed byR1881 exposure (10nM) for 24 hours. The
mediumwas then replaced with R1881-free medium containing
1% stripped serumwith or without metformin (10mM). After 4
hours, cells were incubated in the pres-
ence or absence of 10nM IGF-I for 8
hours and subjected to fluorescence-ac-
tivated cell sorting analysis as previously
described (22).
Densitometric and statistical
analysis
Densitometry results were obtained
by using GelEval 1.22 software. Differ-
ences between means were evaluated by
ANOVA (one- or two-way when appro-
priate) followed by post hoc analysis of
significance (Bonferroni test). The level
of significance was set at P .05. Statis-
tical analysis was performed with
GraphPadPrism5 (GraphPadSoftware).
Data are expressed as mean  SEM.
Results
Metformin inhibits androgen-
mediated IGF-IR up-regulation
and promoter activity
LNCaP cells were exposed to
R1881 (10nM) for 6, 24, and 48
hours in the presence or absence of
metformin (10mM). In accordance
with our previous studies (5), IGF-IR
was clearly up-regulatedafter 24and
48 hours of exposure toR1881,with
a maximum increase of approxi-
mately 10  3-fold over basal at 48
hours (Figure 1A).Metformin signif-
icantly inhibited R1881-mediated
IGF-IR up-regulation (up to 62 
2% and 56 5% of untreated at 24
and at 48 h, respectively). In con-
trast, neither R1881 nor metformin
affected the expression of the IGF-IR
homolog insulin receptor (IR), indi-
cating that these regulatory mecha-
nisms are specific for the IGF-IR
(Figure 1A). Dose response experi-
ments indicated that the inhibitory
effect of metformin starts at 1mM–
3mM and reaches a maximum at
10mM (Figure 1B).
We then evaluated whether met-
formin could inhibit IGF-IR up-reg-
ulation at the level of mRNA and
Figure 1. Metformin inhibits androgen-mediated IGF-IR protein, mRNA up-regulation, and IGF-
IR promoter activity. A, Time-course analysis of IGF-IR protein expression. Cells were serum
starved for 24 hours and then preincubated with 10mM metformin (Met) for 4 hours before
adding 10nM R1881 for the indicated time points. Cells were therefore solubilized and analyzed
by Western blotting. ns, nonstatistically significant (P  .05); *, P  .05; **, P  .005; ***, P 
.0005 (untreated vs R1881 or R1881 vs R1881 plus metformin). B, Dose response of IGF-IR
protein expression. Cells were serum starved for 24 hours and then preincubated with different
concentrations of metformin 4 hours before adding 10nM R1881 for 24 hours. Cells were then
lysed and analyzed by Western blotting. Filters were probed with antibodies specific for IGF-IR
and IR. Immunoblotting with anti--tubulin was used to control protein loading. ***, P  .0005
(R1881 vs R1881 plus 3mM and 10mM metformin). The top panels in A and B show a
representative experiment. The histograms represent the mean  SEM (error bars) of
densitometric analyses of 4 separate experiments. C, IGF-IR mRNA expression. The conditions
were as in A and relative of IGF-IR mRNA expression measured by SYBR Green Chemistry. -
Actin was used as an endogenous control for normalization. Bars, mean  SEM of 4
independent experiments. ns, not statistically significant (P  .05); *, P  .05; ***, P  .0005
(untreated vs R1881 or R1881 vs R1881 plus metformin). D, IGF-IR promoter activity. LNCaP cells
were transiently transfected with plasmids encoding the full-length IGF-IR promoter-luciferase
vector and then pretreated with 10mM metformin before adding 10nM R1881 for 48 hours.
Columns, mean of 3 separate experiments, normalized for transfection efficiency with a GFP
vector. **, P  .005; ***, P  .0005 (untreated vs R1881-treated cells, and R1881 vs R1881
plus metformin). Statistical significance was calculated using one-way ANOVA followed by
Bonferroni test.
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IGF-IR promoter activity. In time-course experiments,
R1881 increased IGF-IR mRNAwith an effect that starts
at 6 hours (5  0.8-fold over basal) and reaches a maxi-
mum at 48 hours (43  8-fold over basal) (Figure 1C).
Metformin (10mM) significantly reduced this R1881 ef-
fect both at 24 and 48 hours (Figure 1C). At 48 hours,
IGF-IR transcript was approximately 40% of peak stim-
ulation obtained by R1881. This effect was also specific
for the IGF-IR, because IRmRNA expression was neither
affected by R1881 nor bymetformin incubation (data not
shown).
To ascertain whether metformin inhibits R1881 effect
at the level of IGF-IR promoter, a full-length IGF-IR pro-
moter-luciferase construct was transfected in LNCaP
cells. Promoter activation was evaluated as luciferase ac-
tivity after stimulationwithR1881 for 6, 24, and 48hours
in the presence or absence of metformin. R1881 increased
the activity of the IGF-IR promoter starting at 6 hours
(data not shown), with amaximum of 1.5 0.7-fold over
basal at 48 hours (P  .0005) (Figure 1D). Metformin
significantly inhibited IGF-IR promoter activation by
R1881 (Figure 1D).
We previously reported that androgens are also able to
up-regulate IGF-IR protein and increase IGF-IR promoter
activity in other cell models, including HEK293 cells
transfected with a wild-type AR (ARwt) expression con-
struct (5). Here, we asked whether metformin was also
able to block these effects in ARwt-transfected HEK293
cells aswell as in a secondAR humanprostate cancer cell
line, VCaP cells. In both cell lines, R1881 inducedmarked
IGF-IR up-regulation, which was strongly inhibited by
metformin (Supplemental Figure 1A, published on The
Endocrine Society’s Journals Online web site at http://en-
do.endojournals.org). Similarly, in both cell lines, R1881
significantly increased IGF-IR promoter activity, which
was completely blocked bymetformin (Supplemental Fig-
ure 1B).
Metformin inhibits androgen-dependent CREB
activity and phosphorylation
We previously demonstrated that, in LNCaP cells, an-
drogens activate CREB and that CREB-dependent stimu-
lation of IGF-IR promoter activity is essential for andro-
gen-induced IGF-IR up-regulation (6). According to these
data,CREB silencing by specific shRNAabolished IGF-IR
up-regulation in response to R1881 (Figure 2A). We then
evaluated whether the inhibitory effect of metformin may
be mediated by the inhibition of androgen-induced CRE
activity. To this aim, a full-length CRE-Luc construct was
cotransfected together withH2BGFP vector, andCRE ac-
tivation was measured as luciferase activity after stimula-
tion with 10nMR1881. We found that R1881 stimulates
CRE activity by approximately 2-fold over the basal and
that eithermetformin or aNCREB construct completely
blocks this activation.Metformin had no additional effect
in the presence of N CREB (Figure 2B). Similar results
were obtained in HEK293 cells cotransfected with an AR
expression construct and a full-length CRE-Luc plasmid
(Supplemental Figure 1C).
We then evaluated whether metformin inhibits CREB
Ser133 phosphorylation, which is associated with CREB
activation.We found thatmetforminaffectsCREBSer133
phosphorylation in a differentway, depending on the time
of drug exposure. Indeed, in cells preincubated for 6
hours, both metformin and R1881 significantly increased
CREB phosphorylation, and the combination of the 2
drugs further increased it. After 24 hours of exposure,
metformin alone increased CREB phosphorylation
slightly but induced a reduction of R1881-dependent
CREB phosphorylation. At 48 hours, metformin did not
affect basal CREB phosphorylation but strongly inhibited
R1881-induced CREB phosphorylation (Figure 2C).
Taken together, these data indicate that the inhibition
of CREB phosphorylation and activity is crucial for met-
formin-induced inhibition of androgen-induced IGF-IR
up-regulation.
Metformin affects the compartimentalization of
CREB cofactor CRTC2
The transcriptional activity of CREB-dependent target
genes is affected by CREB binding to its coactivators CBP
and CRTC2. In hepatocytes, AMPK, induced by starva-
tion or metformin, phosphorylates CRTC2 at Ser171
causing its interaction with 14–3-3 proteins and seques-
tration in the cytoplasm. By contrast, glucose and hor-
mones lead to CRTC2 dephosphorylation and dissocia-
tion from 14–3-3 proteins. Dephosphorylated CRTC2
translocates into the nucleus and promotes CREB-depen-
dent transcription of gluconeogenic gene expression (7).
We hypothesized, therefore, that in LNCaP cells, met-
formin may block androgen-induced IGF-IR up-regula-
tion by inducing the dissociation of the CREB-CBP-
CRTC2 complex via CRTC2 phosphorylation, which
would lead to its nuclear exclusion and degradation.
We first evaluated whether metformin could affect the
cellular compartimentalization of CRTC2 in LNCaP cells
treated with R1881, by using immunofluorescence and
confocal microscopy. Both in basal conditions and after
metformin exposure, CRTC2was exclusively localized in
the cytoplasm, whereas it translocated into the nucleus in
androgen-stimulated cells (Figure 3A).Coincubationwith
metformin prevented CRTC2 nuclear translocation (Fig-
ure 3A). We then studied the phosphorylation status of
CRCT2 after metformin and R1881 and found that met-
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formin stimulates CRTC2 S171 phosphorylation,
whereas R1881 decreases it. The combination treatment
prevented R1881 effect (Figure 3B). Next, we evaluated
the effect of CRTC2 silencing on androgen-induced
IGF-IR and CRE promoter activation. We found that
CRTC2 silencing reduces R1881
stimulation on both IGF-IR and
CRE promoter activities (Figure 3, C
and D). Taken together, these data
suggest that metformin may affect
the transcriptional activity of the
CREB-CBP-CRTC2 complex on
IGF-IRpromoter by inducingCRTC2
S171 phosphorylation.
Involvement of AMPK/mTORC1/
p70S6K and p53/REDD1
pathways in the inhibitory
effect of metformin
Metformin pleiotropic actions
mostly arise from the activation of
the serine/threonine kinase 11
(LKB1)/AMPK pathway, which, in
turn, inhibits the mTORC1/p70S6K
pathway. Indeed, in LNCaP cells,
metformindoesinhibitthemTORC1/
p70S6K pathway, although this ef-
fect has been reported to be AMPK
independent and to require p53-me-
diated REDD1 up-regulation (14).
Because the mTORC1/p70S6K
pathway may regulate CREB tran-
scriptional activity, we evaluated the
possible involvement of this path-
way in metformin-mediated inhibi-
tion of IGF-IR up-regulation.
First, we found that R1881 mark-
edly stimulates p70S6K phosphoryla-
tion, used as a read out of mTORC1
activity, whereas metformin inhibits
p70S6K phosphorylation dose de-
pendently, in strict correlation with
the inhibition of IGF-IR up-regula-
tion (Figure 4A). The activity of the
TORC1 complex is regulated byAkt
(PKB) but also by other kinases, in-
cluding 90 kDa ribosomal S6 kinase
(p90RSK) (23). In LNCaP cells, Akt
(PKB) is constitutively activated, due
to a phosphatase and tensin homo-
logue deleted on chromosome ten
(PTEN) mutation, and Akt (PKB)
phosphorylation was only slightly
enhanced by R1881 (Figure 4A). However, metformin,
especially at 10mM, inhibitedAkt (PKB) phosphorylation
(Figure 4A). We found that inhibition of the mTORC1/
p70S6Kpathway by rapamycin reduced androgen-depen-
Figure 2. Metformin inhibits androgen-induced IGF-IR up-regulation by inhibiting CREB activity
and phosphorylation. A, Androgen-induced IGF-IR up-regulation after CREB silencing. LNCaP
cells were transiently transfected with shRNAs direct to CREB or scrambled shRNAs. After 24
hours, cells were serum starved for 24 hours and then were treated with metformin (10mM) in
association or not with R1881 (10nM) for further 24 hours. Cells were lysed and analyzed by
Western blotting. Filters were probed with antibodies specific for IGF-IR and CREB.
Immunoblotting anti--tubulin was used to control protein loading. The histogram represents the
mean  SEM (error bars) of densitometric analyses of 3 separate experiments. ns, not statistically
significant (P  .05); ***, P  .0005 (untreated vs R1881, and R1881 vs R1881 plus metformin)
B, Effect of NCREB mutant on metformin effect. LNCaP cells were transiently cotransfected
with plasmids encoding NCREB mutant in the presence of a CRE-Luc construct. Cells were
serum starved for 24 hours and then pretreated with 10mM metformin (10mM) 4 hours before
adding R1881 (10nM) for further 24 hours. After drug exposure, CRE activity was measured.
Columns, mean of 3 independent experiments normalized with a GFP vector. ns, not statistically
significant (P  .05); **, P  .005; ***, P  .0005 (untreated vs R1881, and R1881 vs R1881
plus metformin). C, Time course of CREB phosphorylation by metformin with or without R1881.
Cells were serum starved for 24 hours and then pretreated with 10mM metformin (Met) for 4
hours before adding 10nM R1881 for the indicated time points. Cells were, therefore, solubilized
and analyzed by Western blotting. The top panel shows a representative experiment. The
histogram represents the mean  SEM (error bars) of densitometric analysis of 3 separate
experiments. ns, not statistically significant (P  .05); ***, P  .0005 (untreated vs metformin or
R1881 vs R1881 plus metformin). Statistical significance was calculated using one-way ANOVA
followed by Bonferroni test.
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dent IGF-IR up-regulation both at the protein (Figure 4B)
and mRNA levels (Figure 4C), mirroring metformin ac-
tion.Rapamycin also reproducedmetformin effects on the
IGF-IR promoter (Figure 4D), indicating that mTORC1/
p70S6K activity might be involved in mediating met-
formin effects. A second inhibitor of the mTORC1/
p70S6K pathway, tensirolimus, showed similar effects
than rapamycin (data not shown). We then silenced each
of the 2 pathways, AMPK and p53/REDD1, possibly in-
volved in the inhibitionofmTORC1/p70S6Kactivity, and
evaluated whether this could revert
the effects of metformin. We found
that AMPK silencing partially af-
fected metformin-dependent inhibi-
tion of R1881-induced IGF-IR
overexpression (Figure 5A) and pro-
moter activation (Figure 5B).
REDD1silencingonlymarginally af-
fected IGF-IR overexpression (Fig-
ure 5, C and D). Because REDD1 is
downstream p53 (24), we evaluated
whether p53 silencing elicited simi-
lar effects. However, p53 silencing
did not affect IGF-IR expression and
promoter activity in response to ei-
ther R1881 or metformin, and the
combination of REDD1 and p53 si-
lencing was not different from
REDD1 silencing alone (Figure 5, C
and D). Altogether, these results in-
dicate that, in LNCaP cells, mTOR/
p70S6K activity plays a role in andro-
gen-mediated IGF-IR up-regulation
andthatmetformininhibitsandrogen-
dependentmTORC1/p70S6Kactivity
through mechanisms that are only
partially dependent on AMPK activa-
tion and marginally affected by the
p53/REDD1 pathway.
Metformin inhibits c-Src
recruitment to AR
The activation of membrane-ini-
tiated AR signaling is originated by
androgen-induced recruitment of
AR to c-Src, subsequent c-Src activa-
tion, and AR/c-Src complex interac-
tion with other relevant receptors
and signaling molecules (19). Ac-
cording to our previous results, AR
recruitment to c-Src and c-Src acti-
vation are crucial steps in mediating
CREB activation and IGF-IR pro-
moter activity through the ERK/p90RSK pathway (6). In
fact, Src kinase activity inhibition with PP2 was able to
block IGF-IR up-regulation by androgens (5). We then
evaluated whether metformin was able to prevent AR re-
cruitment to c-Src. Indeed, cell exposure to 10mM met-
formin for either 1 or 24 hours completely inhibited the
formation of the AR/c-Src complex and downstream ac-
tivation of p70S6K (Figure 6, A and B). As expected, a
similar effect was obtained after Src kinase activity inhi-
Figure 3. Metformin inhibition of androgen-dependent IGF-IR up-regulation requires CREB
cofactor CRTC2. A, CRTC2 localization by immunofluorescence. LNCaP cells were serum starved
for 24 hours and then pretreated with metformin (Met) (10mM) for 4 hours followed by R1881
exposure (10nM for 24 h). Cells were then plated on cover slips, fixed, and stained for CRCT2
(red) and filamentous actin (phalloidin, green). Nuclei were visualized with Hoechst (blue). The
images presented are representative of most cells examined for that treatment. B, Effect of
metformin treatment in presence or absence of R1881 on CRCT2 phosphorylation at Ser171.
LNCaP cells were serum starved for 24 hours and then pretreated with metformin (30mM) for 4
hours followed by 30 minutes of R1881 (10nM) exposure. Cells were, therefore, solubilized and
analyzed by Western blotting. The top panel shows a representative experiment. The histogram
represents the mean  SEM (error bars) of densitometric analysis of 3 separate experiments.
Activity of IGF-IR promoter (C) and CRE (D) after CRCT2 silencing. LNCaP cells were transiently
transfected with siRNAs to CRCT2 or scrambled shRNAs and, after 24 hours, were transfected
again with plasmids encoding the full-length IGF-IR promoter-luciferase vector (C) or CRE-Luc
construct (D). Twelve hours after transfection, cells were serum starved for 10 hours and then
pretreated with metformin (10mM) before adding R1881 (10nM) for further 24 hours. Columns,
means of 3 separate experiments, normalized for transfection efficiency with a GFP vector. In C
and D, ns, not statistically significant (P  .05); *, P  .05; **, P  .005; ***, P  .0005
(untreated vs R1881, and R1881 vs R1881 plus metformin, one-way ANOVA followed by
Bonferroni test).
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bition with PP2 (Figure 6, C and D).
These data indicate that metformin
may inhibit the R1881-induced AR/
c-Src complex formation and Src ki-
nase activity, which is the very early
step of membrane-initiated AR ef-
fects, to a similar degree than the Src
kinase inhibitor PP2. Similarly, met-
formin inhibited the formation of
R1881-induced AR/c-Src complex
also in VCaP and in ARwt-trans-
fected HEK293 cells (Supplemental
Figure 1D).
To confirm that the inhibitory ef-
fect of metformin on androgen-in-
duced IGF-IR promoter activity was
dependent on c-Src association with
AR, we used a peptide (S1 peptide),
encompassing the 377–386 amino
acid AR sequence, that inhibits c-Src
recruitment toARby inhibiting the in-
teraction between the AR prolin-rich
sequence and the SrcHomology3Do-
mainofSrckinase (19).We found that
S1 peptide, similarly to metformin,
abolished IGF-IR promoter activity
induced by R1881 (Figure 6E).
AR tyrosine phosphorylation is
an important event for prostate tu-
mor growth, sensitivity to IGF-I re-
sponses, and progression to castra-
tion-resistant stage (25). We,
therefore, evaluated the effect of
R1881, metformin, and the combi-
nation of both drugs on AR tyrosine
phosphorylation status. We found
that, in LNCaP cells, AR is constitu-
tively tyrosine phosphorylated, and
this phosphorylation was signifi-
cantly enhancedby10nMR1881 for
2 minutes. Metformin (10mM for 1
or 24 h) slightly reduced basal AR
phosphorylation and markedly in-
hibited R1881-induced AR phos-
phorylation (Figure 6, F and G). Al-
together, these results suggest an
additional mechanism of metformin
inhibitory action on R1881 effects.
Figure 7 summarizes the multiple
levels of membrane-initiated andro-
gen effects, which are affected by
metformin.
Figure 4. Involvement of mTORC1/p70S6K pathway in the inhibitory effect of metformin. A,
Akt (PKB) and p70S6K activation in response to metformin (Met) in cells incubated or not with
R1881. Cells were treated as in Figure 1B, lysed, and analyzed by Western blotting. Filters were
probed with antibodies specific for the phosphorylated form (p) of AKT (PKB) and p70S6K. The
same blots were probed with anti-AKT (PKB), anti-p70S6K, and anti--tubulin to control for
protein loading. The top panel shows a representative experiment. The histogram represents the
mean  SEM (error bars) of densitometric analyses of 4 separate experiments after normalization
of each phosphopeptide against the total nonphosphorylated form. ns, not statistically significant
(P  .05) (untreated vs 10mM metformin, pAKT, and pp70S6K analyses); **, P  .005 (R1881 vs
R1881 plus 10mM metformin, pAKT analysis); ***, P  .0005 (R1881 vs R1881 plus 3mM or
10mM metformin, pp70S6K analysis). B, Involvement of the mTOR pathway in IGF-IR up-
regulation by R1881. Cells were serum starved for 24 hours and then pretreated with 10nM
rapamycin (Rapa) for 4 hours followed by 10nM R1881 for further 24 hours. Cells were,
therefore, solubilized and analyzed by Western blotting. Filters were probed with antibodies
specific for IGF-IR and the phosphorylated form (p) of AKT (PKB), p70S6K, and pERK.
Immunoblotting for -tubulin was used to control for protein loading. The top panel shows a
representative experiment. The histogram represents the mean  SEM (error bars) of
densitometric analyses of 3 separate experiments. C, IGF-IR mRNA relative quantification. The
conditions were as in B. IGF-IR mRNA expression was measured by quantitative RTPCR in
SYBR Green Chemistry. -Actin was used as an endogenous control for normalization. Bars,
mean  SEM of 3 independent experiments. ***, P  .0005 (untreated vs R1881, and
R1881 vs R1881 plus rapamycin). D, Cells were transiently transfected with plasmids
encoding the full-length IGF-IR promoter-luciferase vector and then pretreated with 10nM
rapamycin before adding 10nM R1881 for 24 hours. Columns, means of 3 separate
experiments, normalized for transfection efficiency with a GFP vector. **, P  .005; ***,
P  .0005 (untreated vs R1881, and R1881 vs R1881 plus rapamycin). Statistical significance
was calculated using one-way ANOVA followed by Bonferroni test.
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Metformin inhibits the
androgen-mediated
enhancement of IGF-I biological
effects
In prostate cancer cells, the
IGF-IR up-regulation induced by an-
drogens sensitizes cells to IGF-I-medi-
ated biological effects (5). We, there-
fore,evaluatedwhethermetformin,by
inhibiting androgen-dependent IGF-IR
up-regulation, was able to prevent cell
sensitization to IGF-I biological effects.
Serum-starved cells were preincubated
ornotwithR1881(10nM)for24hours.
After medium change, cells were ex-
posedtoIGF-I(10nM)inthepresenceor
absence of metformin (10mM). In cells
preincubated with R1881, cell prolifer-
ation and invasion in response to IGF-I
were significantly higher than in cells
nonpreincubatedwithR1881(Figure8,
A and B). Interestingly, this R1881
primingeffectonbothIGF-Iactionswas
blockedbymetformin(proliferationde-
creased from 215 2% to 118 5%,
and cell invasiondecreased from225
5% to 120 3%) (Figure 7, A and B).
Similarresultswereobservedincellcycle
analysis experiments (Figure 8C), in
which cell cycle progression, observed
after IGF-I in androgen preincubated
cells, was almost abrogated by met-
formin (SG2/Mphase decreased from
1354%to1003%).Furthermore,
insoft-agarassay,bothLnCaPcells(Fig-
ure 8D) and VCaP cells (Supplemental
Figure 1E) cotreated with metformin
and R1881 formed fewer and smaller
colonies compared with cells treated
withR1881alone, indicatingadecrease
in anchorage-independent growth. Al-
together, these data suggest that met-
formin by inhibiting androgen-medi-
ated IGF-IR up-regulation severely
reduced both cell proliferation, inva-
sion, and clonogenic capacity.
Discussion
We have previously shown that, in
prostate cancer cells, androgens in-
Figure 5. Involvement of AMPK and p53/REDD1 pathways in the inhibitory effect of metformin.
A, Androgen-stimulated IGF-IR up-regulation after AMPK silencing. Cells were transiently
transfected with siRNAs direct to AMPK or scrambled siRNAs. After 24 hours, cells were serum
starved for 24 hours and then treated with metformin (Met) (10mM) 4 hours before the
incubation or not with R1881 (10nM) for further 24 hours. Then cells were lysed and analyzed by
Western blotting. Filters were probed with antibodies specific for IGF-IR and AMPK. Anti--
tubulin immunoblotting was used to control protein loading. The histogram represents the
mean  SEM (error bars) of densitometric analyses of 3 separate experiments. *, P  .05;
**, P  .005; ***, P  .0005 (untreated vs R1881 and R1881 vs R1881 plus metformin, one-
way ANOVA followed by Bonferroni test). B, Androgen-stimulated IGF-IR promoter activity after
AMPK silencing. Cells were transiently transfected with siRNAs direct to AMPK or scrambled
siRNAs. After 24 hours, cells were transiently transfected with plasmids encoding the full-length
IGF-IR promoter-luciferase vector. Twelve hours after transfection cells were serum starved for 10
hours and then pretreated with metformin (10mM) followed by 10nM R1881 for further 24
hours. Columns, mean of 3 separate experiments, normalized for transfection efficiency with a
GFP vector. **, P  .005; ***, P  .0005 (untreated vs R1881 and R1881 vs R1881 plus
metformin, one-way ANOVA followed by Bonferroni test). C, Androgen-stimulated IGF-IR up-
regulation after p53 and/or REDD1 silencing. Cells were transiently transfected with siRNAs direct
to p53 and/or REDD1 or scrambled siRNAs and then treated as in A. Filters were probed with
antibodies specific for IGF-IR, p53, and REDD1. Immunoblotting anti--tubulin was used to
control protein loading. The histogram represents the mean  SEM (error bars) of densitometric
analyses of 3 separate experiments. *, P  .05; ***, P  .0005 (untreated vs R1881, and R1881
vs R1881 plus metformin, one-way ANOVA followed by Bonferroni test). D, Androgen-stimulated
IGF-IR promoter activity after p53 and/or REDD1 silencing. Cells were transiently transfected with
siRNAs direct to p53 and/or REDD1 or scrambled siRNAs and then treated as in B. Columns,
means of 3 separate experiments, normalized for transfection efficiency with a GFP vector.
*, P  .05; **, P  .005; ***, P  .0005 (untreated vs R1881 and R1881 vs R1881 plus
metformin). Statistical significance was calculated by one-way ANOVA followed by Bonferroni
test.
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duce significant up-regulation of the
IGF-IR,which sensitizes cells to IGF-
I-induced growth and invasion (5,
6). This androgen-dependent effect
occurs through membrane-initiated
events, which involve the formation
of multiprotein complexes contain-
ing AR and Src and subsequent acti-
vation of c-Src/ERK/p90RSK cas-
cade that ultimately induces CREB-
dependent activation of IGF-IR
promoter and increased IGF-IR
mRNA transcription (6).
In the present study, we found
that, in LNCaP prostate cancer cells,
metformin inhibits androgen-in-
duced IGF-IR up-regulation as well
as IGF-I protumor effects. Met-
formin inhibited the stimulation of
CREB phosphorylation and activity
induced by androgens with conse-
quent inhibition of androgen-in-
duced IGF-IR promoter activity.
Thesemetformin effectswere not ex-
clusive of LNCaP cells but also ob-
served in a secondAR prostate can-
cer cell line, VCaP, and in AR-
transfected HEK293.
Metformin effects are believed to
mostly involve the activation of the
LKB1/AMPK pathway. AMPK acti-
vation bymetformin appears to be di-
rectly involved in the inhibition of
mTORC1 complex activity, the de-
crease of cyclin D levels, and the up-
regulation of p53 (10, 11, 14). Recent
studies have suggested, however, that
metformin may also have AMPK-in-
dependent effects (10, 13, 14). How-
ever, the effects of metformin at the
level of membrane-initiated androgen
actions are unknown, and the under-
standing of these effects may show
greatpotential inprostatecancerman-
agement. Given the pleiotropic effects
of metformin, we aimed at evaluating
which mechanism is primarily associ-
ated with the inhibition of androgen-
mediated up-regulation of IGF-IR.
When we evaluated the possible
AMPK involvement on the met-
formin inhibitory action, we found
A
E F G
B C D
Figure 6. c-Src recruitment to AR. A and B, c-Src binding with AR after metformin (Met)
treatment with or without R1881. Cells were serum starved for 24 hours and then treated with
metformin (10mM) for 1 hour (A) or for 24 hours (B) followed by the exposure to 10nM R1881
for 2 minutes. Cells were then solubilized, and the lysates were immunoprecipitated with an anti-
Src-specific antibody and analyzed by Western blotting. Total lysates (input) were also evaluated
as a control. Filters were probed with anti-AR, anti-Src, anti-pp70S6K, and anti--tubulin
antibodies as indicated. The panel shows a representative experiment of 3. The histogram
represents the mean  SEM (error bars) of densitometric analyses of AR and pp70S6K for the 3
experiments. *, P  .05; **, P  .005 (R1881 vs R1881 plus metformin). C and D, Cells were
serum starved for 24 hours and then treated with the Src inhibitor PP2 (10M) for 1 hour (C) or
for 24 hours (D) followed by the exposure to 10nM R1881 for 2 minutes. Cells were then
harvested as in A. *, P  .05; **, P  .005 (R1881 vs R1881 plus PP2). E, IGF-IR promoter activity
induced by androgens is inhibited by c-Src/AR interaction inhibitory peptide (S1). LNCaP cells
were transiently transfected with plasmids encoding the full-length IGF-IR promoter-luciferase
vector. Cells were serum starved for 24 hours and then pretreated with 10mM metformin or
1nM the c-Src/AR interaction peptide (S1) before adding 10nM R1881 for 24 hours. Columns,
means of 3 separate experiments, normalized for transfection efficiency with a GFP vector. **,
P  .005; ***, P  .0005 (untreated vs R1881-treated cells, and R1881 vs R1881 plus
metformin or peptide S1). F and G, AR phosphorylation after metformin treatment in presence or
absence of R1881. Cells were serum starved for 24 hours and then treated with metformin
(10mM) for 1 hour (F) or for 24 hours (G) followed by 10nM R1881 exposure for 2 minutes. Cells
were then solubilized, and the lysates were immunoprecipitated (IP) with an anti-phospho
tyrosine (pY) (4G10)-specific antibody and analyzed by Western blotting. Total lysates (input)
were also evaluated as a control and immunoblotted with anti-AR and anti--tubulin antibodies,
as indicated. The panel shows a representative experiment of 3. The histogram represents the
mean  SEM (error bars) of densitometric analyses of the experiments. **, P  .005 (R1881 vs
R1881 plus metformin). Statistical significance was determined by one-way ANOVA followed by
Bonferroni test.
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that AMPK silencing was associated with some reduction
of metformin effect, indicating that this is only partially
dependent on AMPK activation. AMPK may inhibit
CREB transcriptional activity by 2 different mechanisms
involving both the CREB-CBP-CRCT2 complex (26–28)
and the mTORC complex (16, 29). According to the first
mechanism, described in hepatocytes,metformin-induced
inhibition of CREB transcriptional activity involves
AMPK-dependent phosphorylation of CREB cofactor
CRTC2 at Ser171 causing its sequestration in the cyto-
plasm by interaction with 14–3-3 proteins (26–28). On
the other hand, CRTC2 dephosphorylation causes its
translocation to the nucleus, where it contributes to the
formationof theCREB-CBP-CRTC2complexandCREB-
dependent transcription (7).
In unstimulated cells, we found that CRCT2 is phos-
phorylated at Ser171 and almost entirely located in the
cytoplamic compartment. Cells exposure to R1881 in-
duced CRCT2 dephosphorylation and nuclear transloca-
tion. Both events were prevented by metformin. Further-
more, CRCT2 silencing reduced R1881 stimulation of
IGF-IR and CRE promoter activities. This mechanism,
therefore,maypartially account for the inhibitory effect of
metformin, and for the first time, it is described in cancer
cells. Metformin also contributed to inhibit CRE activity
by inhibiting androgen-induced CREB Ser133 phosphor-
ylation despite a transient increase in CREB phosphory-
lation. Although the mechanism(s) by which metformin
transiently increaseCREBphosphorylation is unclear, it is
accepted that transient CREB phosphorylation is a poor
inducer of CREB-mediated transcription, which requires
prolonged and strong CREB phosphorylation (17).
Next, we found that mTORC1 complex is a key me-
diator of androgen-induced IGF-IR up-regulation, be-
cause mTORC1 inhibition by rapamycin or tensirolimus
blocked IGF-IR up-regulation and its promoter activity. It
is well known that metformin may inhibit mTORC1
through AMPK (29). AMPK inhibits mTORC1 by induc-
ing Tuberous Sclerosis Complex 2 (TSC2) Ser1345 phos-
phorylation,which stimulates itsGTPase activity (30), but
also by inducing raptor phosphorylation, which causes
raptordissociation frommTOR(31).AlthoughmTORC1
inhibition by metformin is usually AMPK dependent, in
LNCaP cells,metforminmay inhibitmTORC1 activity by
an AMPK-independent mechanism, which involves p53-
dependent up-regulation of REDD1 (14). REDD1, in
turn, suppresses mTORC1 activity by displacing 14–3-3
proteins from TSC2, thus releasing TSC2 from inhibition
(32). We, therefore, evaluated whether these mechanisms
may account for metformin effects.
Metformin inhibited R1881-dependent p70S6K phos-
phorylation, used as readout of mTORC1 activity. How-
ever, AMPK silencing only partially affected the inhibitory
effects of metformin on IGF-IR overexpression and pro-
moter activation,whereasREDD1 silencing hadonly amar-
ginal effect. Because REDD1 induction by metformin is
downstream of p53, we also evaluated the effect of p53 si-
lencingaloneor incombinationwithREDD1depletion.Nei-
ther of these conditions, however, significantly affectedmet-
formin inhibitory action. Basal IGF-IR levels were up-
regulatedbyp53silencing, inagreementwith the central role
playedbyp53asnegativeregulatorof IGF-IRpromoter (33).
These data are in partial agreement with previous findings
showing that, inLNCaPcells,mTORC1 inhibition bymet-
formin is independent by AMPK (14). However, in con-
trast to our results, these authors found that metformin
effect was mediated by REDD1 up-regulation.
Taken together, our data show that, in LNCaP cells,
AMPK is a weak inhibitor of androgen-stimulated
mTORC1 activity and that REDD1 has a marginal role.
One possible interpretation of these data is based on the
well-known presence of an activating mutation of PTEN
in LNCaP cells (34). PTEN mutation causes constitutive
activation of Akt (PKB), which phosphorylates TSC2 at
multiple sites, thus inactivating its Ras homolog enriched
in brain GTPase activity and inducing constitutive
Figure 7. Cross talk between metformin, androgens, and IGF system
and molecular mechanisms of metformin inhibitory effects. In prostate
cancer cells, androgens up-regulate IGF-IR by inducing CREB
transcriptional activation through membrane-initiated activation of the
Src/MAPK/phosphoinositide 3-kinase (PI3K) pathway. The molecular
mechanisms by which metformin may disrupt this androgen effect
include: 1) inhibition of androgen-induced TORC2 dephosphorylation
and nuclear translocation with consequent reduction in CREB/TORC2
complex transcription activity; 2) inhibition of mTOR/p70S6K signaling,
partially through the AMPK and REDD1 pathways; and 3) Disruption of
AR/c-Src interaction and inhibition of AR phosphorylation. Ras, rat
sarcoma; Raf, rapidly accelerated fibrosarcoma; Mek, mitogen-
activated protein kinase kinase.
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Figure 8. Metformin inhibits the androgen-mediated enhancement of IGF-I biological effects. A, Cell proliferation. LNCaP cells were grown in 96-well
plates, serum starved for 24 hours, and preincubated with or without R1881 (10nM) in the presence or absence of metformin (Met) (10mM). After 24
hours, the medium was then replaced with R1881-free medium containing 1% stripped serum, and cells were incubated with or without 10nM IGF-I for
additional 24 hours, in presence or absence of metformin (10mM). Cell viability was evaluated by MTT assay. Values are expressed as percentages of
untreated cells and represent the mean SEM (errors bars) of 2 separate experiments performed in triplicate. **, P .005; ***, P .0005 (IGF-I vs
basal and IGF-I vs IGF-Imetformin, respectively). B, Invasion. Subconfluent LNCaP cells, serum starved for 24 hours, were preincubated with or without
R1881 (10nM) and in the presence or absence of metformin (10mM). Then, cells were removed from plates with 0.01% trypsin and seeded on
polycarbonate filters. Cells were allowed to migrate to the underside of the top chamber for 18 hours in response to 10nM IGF-I added to the lower
chamber and in the presence or absence of metformin (10mM). Values are mean SEM (errors bars) of 2 separate experiments done in triplicate and are
expressed as percent of untreated cells. **, P .05; ***, P .0005 (IGF-I vs basal and IGF-I vs IGF-Imetformin, respectively). C, Cell cycle progression.
LNCaP cells were treated as in A and then analyzed for their cell cycle profiles. Cell populations positive for propidium iodine staining were evaluated by
fluorescence-activated cell sorting (FACS) analysis, and G0/G1 and G2/M phases were scored. Panels show the cell cycle profile of untreated and
stimulated cells of a representative experiment. Below each cell cycle profile the percentage of cells in S and G2/M phases is indicated. Values are
expressed as percent of basal and are the mean SEM (errors bars) of 2 separate experiments. *, P .05; ***, P .0005 (R1881 vs R1881 plus
metformin in presence or absence of IGF-I, respectively). Statistical significance was calculated using one-way ANOVA followed by Bonferroni test. D,
Colony formation after metformin treatment with or without R1881. The soft-agar colony assay of LnCaP cells was performed as described in Material
and Methods. Cells were cultured for 3 weeks, and the colonies formed were stained with MTT and then photographed.
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mTORC1activation (35–37). It seems likely that this con-
stitutive phosphorylation of TSC2 by Akt (PKB) reduces
the activity of AMPK and of REDD1, which also act on
TCS2 (14).
We then hypothesized that the inhibition of androgen-
induced p70S6K stimulation bymetformin could result by
the disruption of the AR-c-Src complex. As a result of
AR-c-Src association, androgens induce downstream sig-
naling, which involves ERK1/2 and p70S6K. Notably,
metformin was able to block AR association with c-Src.
Disruption of the AR association with c-Src at the cell
membrane appears, therefore, to play an essential role in
metformin antagonism on membrane-initiated androgen
effects.
It has been reported that AR may be tyrosine phos-
phorylated in response to growth factors. This AR mod-
ification may be important for prostate tumor growth,
sensitivity to IGF-I effects, and progression to castration-
resistant stage (25). Thus, we explored the effect of met-
formin and androgens on AR tyrosine phosphorylation.
We found the R1881 mediated AR tyrosine phoshoryla-
tion and that metformin inhibited it, suggesting an addi-
tional mechanism of metformin inhibitory action on
R1881 effects.
Interestingly, in FBS-containing semisolid agar, met-
formin was able also to inhibit R1881-induced enhance-
ment of colony formation, an effect closely related to ma-
lignant cell growth and cancer invasion. These data are
reminiscent of previous results showing that metformin
enhances the antiproliferative and apoptotic effect of bi-
calutamide in prostate cancer cells (12). Several other
studies have provided evidence that metformin may have
therapeutic potential in prostate cancer (10, 14). A recent
retrospective clinical studyhas shown thatmetforminmay
improve recurrence-free survival, distant metastases-free
survival, cancer-specific mortality, and development of
castration-resistant prostate cancer (38). However, the
molecular mechanisms involved are unclear, and authors
mostly refer to the inhibiting effect of LKB1/AMPK on
mTORC1 (8, 9, 11). We now show that, in LNCaP cells
exposed to metformin, AMPK plays a minor role in in-
hibitingmTORC1,whereasmetformin strongly interferes
with membrane-initiated effects of androgens by disrupt-
ing the very early step of this signaling cascade, which
involvesARassociationwith c-Src, andAR tyrosine phos-
phorylation, and also inhibit CRCT2 nuclear transloca-
tion and CREB activation.
Future studies are needed to establish to what extent
ourmechanistic results are generalizable to invivomodels.
Metformin started to be efficacious at a concentration
of 1mMwith a maximal effect observed at 10mM, a con-
centration well within the range used by most in vitro
studies using various cancer cells, including prostate can-
cer cells (1mM–100mM,most often 10mM–20mM) (10–
12, 17). Although, these concentrations are clearly higher
than metformin levels observed in diabetic patients
(mostly 20M) (39), it has been previously shown that
many organs are exposed to metformin concentrations
significantly higher than those present in the bloodstream.
For instance, metformin concentration is much higher in
the portal vein than in the general circulation. Therefore,
liver is exposed to metformin concentration in the milli-
molar range (40). Moreover, metformin is also able to
concentrate in several other organs/tissues in dependence
on its pharmacokinetics and the expression of transport-
ers, such as organic cation transporter (OCT)1, OCT2,
andOCT3. Therefore, salivary glands, stomach, small in-
testine, kidney, and other organs/tissues are all exposed to
metformin concentrations appreciably higher than that
present in the bloodstream (41). Finally, because of its
positive charge, metformin may concentrate by approxi-
mately 1000-fold in mitochondria, to reach millimolar
concentrations in the mitochondrial matrix (42). Further-
more, recent studies have reported that breast stem cancer
cells are sensitive to micromolar concentrations of met-
formin (43), suggesting that subsets of cancer cells with
stem-like featuresmight be able to exquisitely concentrate
metformin. To our knowledge, studies investigating met-
formin concentrations in prostate and prostate cancer tis-
sue are still lacking and are certainly needed, also because
metformin use is associated with all-cause and prostate
cancer-specific mortality among men with diabetes (44).
In conclusion, we have identified a novel potential an-
titumor effect of metformin operating in AR prostate
cancer cells and involving the inhibition of membrane-
initiated androgen effects, adding to the list of the numer-
ous antitumor effects of metformin observed in several in
vitro and in vivo model systems. We have especially char-
acterized the action of metformin in blocking androgen-
induced IGF-IRup-regulation and IGF-I-mediatedbiolog-
ical effects. However, given thatmetformin inhibits a very
early step of membrane-initiated androgen effects, ie, the
association between Src andARandARphosphorylation,
there is thepossibility thatmetforminmayalsoblockother
membrane-initiated effects of androgens. Several evi-
dences indicate that membrane-initiated androgen effects
are enhanced in cancer cells and may play a role in tumor
progression (1–3). Our present findings, therefore, open
the way to a deeper understanding of the potential effects
of metformin in prostate cancer.
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